
    
      Efficacy Evaluation:

      â€¢ Primarily based on clinical inspection of the former 25 cm2 treatment area and count of the
      AK-lesions.

      Safety Evaluation:

        -  Evaluation of adverse events (AEs) and serious adverse events (SAEs)

        -  Evaluation of newly occurred dermal adverse events (AEs) and serious adverse events
           (SAEs) in the previous treatment area at 6 months and 12 months of follow-up (local
           tolerability).

        -  Follow-up of unresolved adverse and serious adverse events that occurred in the previous
           trial SP848-AK-1101.

        -  Follow-up of unresolved abnormal laboratory values that occurred in the previous trial
           SP848-AK-1101.
    
  